Schering/Merck Zetia 6% Market Share Is 1% Ahead Of Goal
This article was originally published in The Pink Sheet Daily
Executive Summary
Prescription growth for the cholesterol drug Zetia has not come at the expense of the Zetia/Zocor fixed-dose combination Vytorin, Schering says. The penetration rate for Vytorin on managed care formularies is over 75%, the company says.